A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE

被引：0
|
作者：
Mantzaris, G. [1 ]
Bressler, B. [2 ]
Kopylov, U. [3 ]
Bassel, M. [4 ]
Brett, N. [4 ]
Colby, C. [5 ]
Lopez, C. [6 ]
Saha, S. [7 ]
Kifnidi, C. [8 ]
Agboton, C. [9 ]
Adsul, S. [9 ]
Demuth, D. [10 ]
Luo, M. [11 ]
Wang, S. [11 ]
Yarur, A. [12 ]
机构：
[1] Evangelismos Med Ctr, Dept Gastroenterol, Athens, Greece
[2] St Pauls Hosp, Dept Gastroenterol, Vancouver, BC, Canada
[3] Sheba Med Ctr, Dept Gastroenterol, Tel Aviv, Israel
[4] Evidera, Real World Evidence, Montreal, PQ, Canada
[5] Evidera, Real World Evidence, San Francisco, CA USA
[6] Takeda Pharmaceut USA Inc, Dept Med Affairs, Deerfield, IL USA
[7] Takeda Canada Inc, Dept Med Affairs, Oakville, ON, Canada
[8] Takeda Hellas SA Athens, Dept Med Affairs, Athens, Greece
[9] Takeda Pharmaceut Int AG, Dept Global Med Affairs, Zurich, Switzerland
[10] Takeda Pharmaceut Int, Evidence Generat & Publicat, Singapore, Singapore
[11] Takeda Pharmaceut Int, Global Outcomes Res, Boston, MA USA
[12] Med Coll Wisconsin, Dept Gastroenterol, Milwaukee, WI 53226 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP55
引用
收藏
页码：S092 / S094
页数：3
相关论文
共 50 条
  • [1] A REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE
    Mantzaris, Gerassimos J.
    Bressler, Brian
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Colby, Chris
    Lopez, Claudia
    Saha, Sumit
    Kifnidi, Christina
    Agboton, Christian
    Adsul, Shashi
    Demuth, Dirk
    Luo, Michelle
    Wang, Song
    Yarur, Andres J.
    GASTROENTEROLOGY, 2020, 158 (06) : S405 - S405
  • [2] A real-world comparison of the effectiveness and safety of vedolizumab and anti-tumor necrosis factor therapies in early treatment initiation with first-line biological therapy in ulcerative colitis: Results from EVOLVE
    Mantzaris, G.
    Bressler, B.
    Kopylov, U.
    Bassel, M.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Yarur, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 119 - 120
  • [3] REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF IN BIOLOGIC-NAIVE ULCERATIVE COLITIS PATIENTS: RESULTS FROM THE EVOLVE STUDY
    Yarur, Andres J.
    Mantzaris, Gerassimos J.
    Silverberg, Mark S.
    Walshe, Margaret
    Zezos, Petros
    Stein, Dara
    Bassel, Marielle
    Lissoos, Trevor
    Lopez, Claudia
    Natsios, Athanasios
    Radulescu, Gabriela
    Patel, Haridarshan
    Demuth, Dirk
    Bressler, Brian
    GASTROENTEROLOGY, 2019, 156 (06) : S637 - S638
  • [4] Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study
    Yarur, A.
    Mantzaris, G.
    Silverberg, M.
    Walshe, M.
    Zezos, P.
    Stein, D.
    Bassel, M.
    Lissoos, T.
    Lopez, C.
    Natsios, A.
    Radulescu, G.
    Patel, H.
    Demuth, D.
    Bressler, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S400 - S401
  • [5] Real World Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naive Ulcerative Colitis and Crohn's Disease Patients: Results From the EVOLVE Study
    Yarur, Andres
    Mantzaris, Gerassimos J.
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Lissoos, Trevor
    Lopez, Claudia
    Natsios, Athanasios
    Kifnidi, Christina
    Saha, Sumit
    Demuth, Dirk
    Patel, Haridarshan
    Bressler, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S460 - S461
  • [6] Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study
    Bressler, B.
    Mantzaris, G.
    Silverberg, M.
    Zezos, P.
    Stein, D.
    Colby, C.
    Lissoos, T.
    Lopez, C.
    Natsios, A.
    Radulescu, G.
    Patel, H.
    Demuth, D.
    Yarur, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S427 - S428
  • [7] REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF IN BIOLOGIC-NAIVE CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
    Mantzaris, Gerassimos J.
    Yarur, Andres J.
    Silverberg, Mark S.
    Zezos, Petros
    Stein, Dara
    Kim, Hankyul
    Lissoos, Trevor
    Lopez, Claudia
    Natsios, Athanasios
    Radulescu, Gabriela
    Patel, Haridarshan
    Demuth, Dirk
    Bressler, Brian
    GASTROENTEROLOGY, 2019, 156 (06) : S638 - S638
  • [8] Real World Experience With Vedolizumab as First-Line Therapy for the Treatment of Ulcerative Colitis
    Ritter, Timothy E.
    Mehta, Samantha A.
    Van Anglen, Lucinda J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S439 - S439
  • [9] Real-World Effectiveness and Onset of Action of Vedolizumab as a First-Line Biologic in Biologic-Naïve Patients With Ulcerative Colitis
    Anyanwu, Precious A.
    Van Anglen, Lucinda J.
    Chou, Chiahung
    Sanchirico, Marie
    Ritter, Timothy E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S) : S876 - S877
  • [10] Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's Disease
    Bressler, Brian
    Yarur, Andres
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Lissoos, Trevor
    Lopez, Claudia
    Natsios, Athanasios
    Saha, Sumit
    Kifnidi, Christina
    Demuth, Dirk
    Patel, Haridarshan
    Mantzaris, Gerassimos J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S373 - S373
12345